Released Aug 13, 2020, after the close
10-Q filed Aug 14, 2020, 45 days after period end · 0000926617-20-000063
Q2 2020 · 10-Q
Revenue$746.00K$746.00K −34.7% vs Q2 2019−38.9% vs Q1 2020
Net Income-$3.83M-$3.83M N/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.04-$0.04 N/M vs Q2 2019N/M vs Q1 2020
Gross Profit$153,000−34.6%
Operating Income-$3,826,000N/M
Operating Cash Flowderived-$3,410,000N/M
Free Cash Flowderived-$3,510,000N/M
Margins · derived
Gross margin20.5%+0.0 pt vs Q2 2019
Operating margin-512.9%−135.9 pt vs Q2 2019
Net margin-513.5%−135.8 pt vs Q2 2019
What the release said
The release
Same quarter
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $746.00K | $1.14M | $708.00K | $898.00K |
| Net Income | -$3.83M | -$4.31M | -$3.05M | -$2.36M |
| EPS Diluted | -$0.04 | -$0.06 | -$0.04 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aspira Women's Health Inc. · CIK 926617 · Engraved from SEC EDGAR